HB 101

Drug Profile

HB 101

Alternative Names: HB-101

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator Hookipa Biotech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 04 May 2017 Pharmacodynamics data from a preclinical study in Cytomegalovirus infections released by Hookipa Biotech
  • 09 Jan 2017 Pharmacodynamics data from a preclinical study in Cytomegalovirus infections released by Hookipa Biotech
  • 01 Jun 2016 Phase-I clinical trials in Cytomegalovirus infections (Prevention) in Belgium (IM) (NCT02798692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top